Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

NCT05016349 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Female

Interventions

DRUG: All trans-retinoic acid
DRUG: 13-Cis Retinoic Acid plus Tocopherol
DRUG: Mifepristone
DRUG: Cannabidiol
DRUG: 9 cis retinoic acid
DRUG: Tamoxifen
DRUG: Standard therapy

Sponsor

Mahmoud Ramadan mohamed Elkazzaz

Collaborators

[object Object]